XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.22.2.2

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION | 9 Months Ended
--- | ---
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION | SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION Supplemental Balance Sheet Information Inventory consisted of the following:
| September 30, 2022 |  | December 31, 2021
Raw materials | $ | 109,480 |  |  | $ | 80,269 |
Work-in-process | 425,505 |  |  | 415,261 |
Finished goods | 304,475 |  |  | 281,139 |
Total inventory | $ | 839,460 |  |  | $ | 776,669 |
Property, Plant and Equipment, Net consisted of the following:
| September 30, 2022 |  | December 31, 2021
Property, plant and equipment, gross | $ | 1,834,220 |  |  | $ | 1,756,035 |
Accumulated depreciation | (782,399) |  |  | (720,574) |
Total property, plant and equipment, net | $ | 1,051,821 |  |  | $ | 1,035,461 |
Depreciation expense, net of amounts capitalized into inventory, for the three and nine months ended September 30, 2022 was $8.7 million and $29.9 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and nine months ended September 30, 2021 was $11.4 million and $35.7 million, respectively. Intangible Assets, Net consisted of the following:
| September 30, 2022 |  | December 31, 2021
Finite-lived intangible assets | $ | 690,334 |  |  | $ | 677,350 |
Accumulated amortization | (336,310) |  |  | (288,698) |
Net carrying value | $ | 354,024 |  |  | $ | 388,652 |
Accounts Payable and Accrued Liabilities consisted of the following:
| September 30, 2022 |  | December 31, 2021
Accounts payable and accrued operating expenses | $ | 207,165 |  |  | $ | 199,678 |
Accrued compensation expense | 161,112 |  |  | 204,446 |
Accrued rebates payable | 71,653 |  |  | 47,987 |
Accrued royalties payable | 14,487 |  |  | 15,215 |
Foreign currency exchange forward contracts | 13,075 |  |  | 6,263 |
Lease liabilities | 9,226 |  |  | 10,464 |
Accrued income taxes | 7,573 |  |  | 1,213 |
Deferred revenue | 415 |  |  | 6,956 |
Other | 8,011 |  |  | 6,043 |
Total accounts payable and accrued liabilities | $ | 492,717 |  |  | $ | 498,265 |
Supplemental Statement of Comprehensive Income (Loss) Information Gain on Sale of Nonfinancial Assets, Net for the nine months ended September 30, 2022 consisted of the completed sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the Food and Drug Administration (FDA) in connection with the U.S. approval of VOXZOGO. As a result of the PRV sale, the Company recognized a $108.0 million net gain on sale of nonfinancial assets in the first quarter of 2022 in the Company's Consolidated Statement of Comprehensive Income.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration